CIK 0001108205 · Non-accelerated filer<br>Smaller reporting company
CURIS INC
Sign in to watch- Ticker
- CRIS
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 043505116
- Phone
- 617-503-6500
- Business address
- 128 SPRING STREET, BUILDING C, SUITE 500, LEXINGTON, MA, 02421
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-07-07 | Rubin Marc Director | Grant or award · Non Qualified Stock Option | +6,800 | $5.29 | $36K | 6,800 |
| 2026-07-07 | KAITIN KENNETH I Director | Grant or award · Non Qualified Stock Option | +6,800 | $5.29 | $36K | 6,800 |
| 2026-07-07 | Hohneker John Director | Grant or award · Non Qualified Stock Option | +6,800 | $5.29 | $36K | 6,800 |
| 2026-07-07 | GREENACRE MARTYN D Director | Grant or award · Non Qualified Stock Option | +6,800 | $5.29 | $36K | 6,800 |
| 2026-07-07 | Borgman Anne Elizabeth Director | Grant or award · Non Qualified Stock Option | +6,800 | $5.29 | $36K | 6,800 |
| 2026-07-07 | Duvall Diantha CFO | Grant or award · Employee stock option (right to buy) | +48,285 | $5.29 | $255K | 48,285 |
| 2026-07-07 | Zung Jonathan B. CDO | Grant or award · Employee stock option (right to buy) | +48,285 | $5.29 | $255K | 48,285 |
| 2026-07-07 | Dentzer James E President & CEO | Grant or award · Employee stock option (right to buy) | +110,090 | $5.29 | $582K | 110,090 |
| 2026-03-31 | KAITIN KENNETH I Director | Purchase | +10,000 | $0.55 | $5K | 11,407 |
| 2026-03-20 | Zung Jonathan B. CDO | Conversion | +66,667 | 66,667 | ||
| 2026-03-20 | Zung Jonathan B. CDO | Conversion · Series B Convertible Preferred Stock | −50 | 0 | ||
| 2026-03-20 | Hamdy Ahmed MD CMO | Conversion | +66,667 | 66,667 | ||
| 2026-03-20 | Hamdy Ahmed MD CMO | Conversion · Series B Convertible Preferred Stock | −50 | 0 | ||
| 2026-03-20 | Duvall Diantha CFO | Conversion | +66,666 | 77,707 | ||
| 2026-03-20 | Duvall Diantha CFO | Conversion · Series B Convertible Preferred Stock | −50 | 0 | ||
| 2026-03-20 | Dentzer James E President & CEO | Conversion | +133,333 | 148,730 | ||
| 2026-03-20 | Dentzer James E President & CEO | Conversion · Series B Convertible Preferred Stock | −100 | 0 | ||
| 2026-03-20 | Rubin Marc Director | Conversion | +26,667 | 28,108 | ||
| 2026-03-20 | Rubin Marc Director | Conversion · Series B Convertible Preferred Stock | −20 | 0 | ||
| 2026-03-17 | Zung Jonathan B. CDO | Grant or award · Series B Convertible Preferred Stock | +50 | 50 |
Page 1 of 17 · 326 trades